Corvus Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
CRVS
CUSIP
221015100
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 221015100 since 12/18/2024, largest first.

Filer % of Class Filed
Orbimed Advisors LLC 13D/A
10.3% 1/27/2026
Event 1/23/2026
Miller Richard A MD 13G/A
7.8% 2/13/2026
Event 12/31/2025
Sirenia Capital Management LP 13G
7.5% 5/15/2026
Event 3/31/2026
BlackRock, Inc. 13G/A 7.5% 7/27/2026
Event 6/30/2026
State Street Corp 13G 5.3% 8/7/2026
Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (4)
Adams Street Partners, LLC 13D/A
3.9% 2/5/2026
Event 1/23/2026
Point72 Asset Management, L.P. 13G/A
0% 5/15/2026
Event 3/31/2026
Samlyn Capital, LLC 13G/A
0% 8/14/2025
Event 6/30/2025
Vanguard Group Inc 13G/A 0% 3/26/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 5 36.1 k $416 k
2026 Q2 187 71.8 M $1.13 B
2026 Q1 175 70.1 M $1.02 B
2025 Q4 136 46.7 M $360 M
2025 Q3 110 41.7 M $307 M
2025 Q2 102 41.9 M $168 M
2025 Q1 106 36.3 M $115 M
2024 Q4 103 37.7 M $202 M
2024 Q3 74 30.1 M $159 M
2024 Q2 54 28.0 M $50.9 M
2024 Q1 55 18.5 M $32.9 M
2023 Q4 55 19.4 M $34.2 M
2023 Q3 57 19.2 M $28.0 M
2023 Q2 59 19.5 M $44.6 M
2023 Q1 39 20.8 M $18.9 M
2022 Q4 46 21.5 M $18.3 M
2022 Q3 50 22.1 M $18.1 M
2022 Q2 53 25.6 M $25.4 M
2022 Q1 67 27.4 M $44.9 M
2021 Q4 77 27.8 M $66.9 M
2021 Q3 77 28.2 M $136 M
2021 Q2 55 23.7 M $63.2 M
2021 Q1 53 20.4 M $62.8 M
2020 Q4 48 16.8 M $59.7 M
2020 Q3 42 17.2 M $69.0 M
2020 Q2 39 20.4 M $55.6 M
2020 Q1 45 20.7 M $43.6 M
2019 Q4 39 20.9 M $114 M
2019 Q3 36 22.9 M $68.9 M
2019 Q2 46 24.3 M $91.0 M
2019 Q1 59 24.8 M $99.5 M
2018 Q4 63 25.3 M $92.7 M
2018 Q3 65 25.7 M $220 M
2018 Q2 58 25.9 M $285 M
2018 Q1 56 25.4 M $289 M
2017 Q4 54 17.4 M $180 M
2017 Q3 54 17.5 M $280 M
2017 Q2 52 17.5 M $212 M
2017 Q1 53 17.3 M $360 M
2016 Q4 54 17.5 M $250 M
2016 Q3 45 16.3 M $268 M
2016 Q2 45 17.3 M $237 M
2016 Q1 32 16.4 M $228 M